UnitedHealth Group is a large integrated health insurer and health‑services provider with multi‑year per‑share revenue growth, strong operating cash generation and high reported gross and operating margins alongside recent volatility in earnings and returns.
On the positive side, revenue per share has been a consistent growth engine—most recent 1‑year revenue‑per‑share growth was 11.8% and split‑adjusted revenue per share reached $491.29—and the five‑year revenue‑per‑share CAGR is roughly 11.72%, supporting a broad top‑line expansion (EPS Diluted & Revenue per Share; Revenue & EPS Growth).
Profitability at the operational level is robust: gross margin remains very high at about 88.7% and operating margin sits near 75.4%, and trailing‑12‑month operating cash flow ($19.70B) has exceeded reported trailing‑12‑month net income ($12.06B), indicating cash generation ahead of accounting earnings (Profit Margin Trends; Earnings Quality Analysis; Strategic Capital Allocation).
Notable weaknesses include meaningful earnings volatility and weakening bottom‑line conversion: diluted EPS turned negative on a year‑over‑year basis most recently (-16.31%) with the latest reported diluted EPS down to $13.23 from $24.27 earlier in 2025, and quarterly net income fell to 10.0M against quarterly revenue of $113.22B, leaving net profit margin at about 2.7% in the most recent quarter (EPS Diluted & Revenue per Share; Revenue & Net Income; Profit Margin Trends).
Return metrics and liquidity have also softened — trailing‑12‑month ROE declined to 12.0% (with ROE growth negative ~‑17.8%) and the current ratio is below 1.0 at 0.8229, highlighting pressure on returns and short‑term liquidity (Return on Equity (ROE)).
Key fundamental metrics to watch going forward are revenue‑per‑share growth and its translation to diluted EPS (current RPS growth 11.8% vs latest EPS $13.23), the relationship of operating cash flow to net income (TTM OCF $19.70B vs TTM net income $12.06B), net profit margin trends (2.7%), ROE (12.0%), the current ratio (0.8229) for liquidity, and the evolving market multiple (most recent P/E 24.9x after a mid‑2025 trough of 13.3x). See Revenue & Net Income, EPS Diluted & Revenue per Share, Revenue & EPS Growth, Profit Margin Trends, Earnings Quality Analysis, Return on Equity (ROE), Strategic Capital Allocation and Price-to-Earnings (PE) Ratio Trend for the underlying data.
The foundation of business quality and long-term value creation
UNITEDHEALTH GROUP INC’s revenue shows a steady multi-year rise, roughly doubling from about $56.6B in late 2018 to just over $113B in the most recent quarter. Revenue climbed through 2024 and into 2025, moving from $100.81B (2024-12-31) to $109.58B (2025-03-31), then to $111.62B (2025-06-30) and $113.16B (2025-09-30), with the latest quarter at $113.22B, indicating sequential growth that has recently flattened near the $113B level.
Net income has been more variable over the same period. After a loss of −$1.41B in 2024-03-31, net income rose to as high as $6.29B in 2025-03-31, then declined to $3.41B (2025-06-30) and $2.35B (2025-09-30), and fell sharply to \$10.0M in 2025-12-31. The most recent quarterly revenue was $113.22B. The most recent quarterly net income was $10.0M.
Why Growth Matters
Consistent revenue and earnings growth are the lifeblood of successful long-term investments. Companies that can grow their top line (revenue) and bottom line (net income) over many years demonstrate they have products or services customers value and are willing to pay for repeatedly.
Revenue Growth shows whether the company is expanding its market reach, gaining market share, or successfully launching new products.Net Income Growth demonstrates the company can convert that revenue into actual profits while managing costs effectively.
Look for steady, sustainable growth rather than erratic spikes. The best businesses compound earnings year after year, creating tremendous value for shareholders over time. Companies that can grow earnings faster than revenue are improving their profitability—a sign of operational excellence and competitive strength.
Year-over-year growth rates for revenue and earnings per share
Reading the Growth Rate Chart
This chart converts the absolute per-share figures into year-over-year percentage changes, making it easy to see whether growth is accelerating, decelerating, or reverting to trend — regardless of the company's absolute size.
Revenue per Share Growth (1-year, split-adjusted) measures how quickly the top line is expanding on a per-share basis. Sustained positive growth signals that the company continues to win customers and grow its addressable market.EPS Diluted Growth (1-year, split-adjusted) measures how quickly earnings are compounding for each shareholder. When EPS growth consistently outpaces revenue growth, operating leverage and margin expansion are at work.
Look for consistency, not just magnitude. A company that reliably grows EPS 10–15% per year is far more valuable than one that alternates between 50% spikes and deep contractions. Negative EPS growth during a period of positive revenue growth is a red flag — costs are rising faster than sales. Quarters where both lines converge near zero or go negative deserve close scrutiny.
How revenue converts to net income for the most recent annual period
Over the period Jan 2025 to Dec 2025, Unitedhealth Group Inc converts approximately 89¢ of every revenue dollar into gross profit (gross margin: 88.7%).After accounting for operating expenses and taxes and expenses, the company retains 2.7% as net profit margin, resulting in $12.06B in net earnings.
Period Information
Report Type: Annual (10-K)
Period: Jan 2025 to Dec 2025
Revenue composition by disclosure category for the latest period
revenues from provision of primary, specialty and surgical care; care management; wellness and consumer engagement services; post-acute care planning; in-home and virtual care; advanced digital health technologies; health financial services including Optum Financial and Optum Bank which generate fees and investment and interest income on managed funds and loans. Revenue arrangements include fully accountable value-based arrangements (monthly premium in exchange for assumed responsibility for health care costs), administrative fee arrangements (monthly management fees), and fee-for-service arrangements (contracted fees for delivered medical services).
revenues from data, analytics, research, consulting, technology, software/information products and professional services and managed services that simplify clinical, administrative and financial processes. Many offerings are delivered under multi-year contracts tracked in an order backlog and include services to health systems, health plans, state governments and life sciences companies.
revenues from pharmacy care services delivered through a retail pharmacy network, home delivery, specialty and community health pharmacies, in-home and community-based infusion services, and rare disease and gene therapy support services, plus direct-to-consumer solutions. Revenues derive from managing prescription drug spend for clients and from clinical programs and utilization management services provided to clients.
revenues from risk-based health benefit products (monthly premiums for assumed medical and administrative risk) and from administrative and management services provided to self-funded employer plans (coordination of services, transaction processing and network access fees). Product categories include consumer engagement plans, traditional medical plans, clinical and pharmacy products and specialty benefits such as vision, dental and other ancillary offerings.
revenues from Medicare Advantage contracts (payments from CMS and in some cases consumer premiums), Medicare Part D plans (stand-alone and those embedded in Medicare Advantage), Medicare Supplement products, and provision of care management, clinical programs and administrative services to Medicare-eligible consumers.
revenues from Medicaid and CHIP managed care contracts and other state program contracts, typically in the form of monthly premiums per member from state programs; revenues relate to administering benefits and care programs for populations served by these state programs.
Analyzing long-term margin stability and competitive positioning
UnitedHealth Group Inc’s gross margin has been high and relatively stable over the period, trading in a narrow band around the high 80s percent. Gross margin peaked near 89.7%–89.8% in 2022–2023 and has eased modestly through 2024–2025 to the high-88% range, most recently 88.7%. Operating margin showed a gradual lift from the low-70s in 2021 toward the mid-70s, holding around 74.6%–75.7% across 2023–2025, with a small dip from 75.7% in mid-2025 to 75.4% in the latest quarter.
Net profit margin has been more variable and has declined over the past year. After a run near 6.0% in 2022–2023, net margin fell through 2024 and into 2025—rising briefly to 5.4% in Q1 2025 before retreating to 2.7% by year-end 2025. The most recent quarterly gross margin was 88.7%, operating margin was 75.4%, and net profit margin was 2.7%.
Understanding Profit Margins
Between Jan 2025 and Dec 2025, Unitedhealth Group Inc converts every dollar of revenue through the following stages:
Sustainable competitive advantages reveal themselves through consistently superior profit margins over extended periods. Companies with durable economic moats maintain pricing power and operational efficiency that competitors struggle to match.
A sign of durable competitive advantage is earning sustained higher margins than competitors.Look for margins that remain stable or improve over time, especially during economic downturns. Declining margins may signal increasing competition, pricing pressure, or deteriorating business fundamentals.
Comparing reported earnings to actual cash generation
Over the most recent year UNITEDHEALTH GROUP INC's trailing twelve-month operating cash flow and net income have both moved lower from mid-2025 peaks. Operating cash flow declined from $28.96B at 2025-06 to $19.70B at 2025-12, while net income fell from $22.11B at 2025-03 to $12.06B at 2025-12. Throughout the recent quarters cash flow remained above net income, so operating cash generation exceeded reported earnings in each of the last several TTM observations.
Notable inflection points in the data include a period in 2021–2022 when operating cash flow turned negative while net income stayed positive, followed by large positive cash flow spikes in 2023 (peaking at $41.38B on 2023-06) and elevated levels through early 2025. Since those peaks, both metrics have moderated into late 2025. The most recent trailing twelve-month operating cash flow was $19.70B and the most recent trailing twelve-month net income was $12.06B.
The Earnings vs. Cash Flow Gap
Reported earnings (Net Income) doesn't always reflect actual cash generation. Companies use accrual accounting, which recognizes revenue when earned and expenses when incurred—not when cash actually changes hands. This creates timing differences and opportunities for accounting discretion that can mask underlying business health.
Net Income (the "earnings" number) can be influenced by non-cash items like depreciation, stock-based compensation, and changes in accounting estimates.Operating Cash Flow, however, shows the actual cash the business generates from its core operations—a harder number to manipulate.
Trailing Twelve Months
What to Look For
Key Insight: Companies with durable competitive advantages typically show operating cash flow that meets or exceeds net income over time, demonstrating they convert accounting profits into actual cash that can be returned to shareholders or reinvested in the business.
Measuring management's efficiency at generating profits from shareholder capital
UNITEDHEALTH GROUP INC's ROE shows a long period of elevated profitability from roughly 2018 through 2023, with trailing‑12‑month ROE generally in the low‑20s and peaks around the mid‑20s (multiple quarters at ~24%). That multi‑year plateau gave way to a drop into the mid‑teens through 2024 (around 14–15%), followed by a brief rebound in early 2025 when ROE rose back above 21% for the March and June 2025 quarters.
In the most recent quarters, the trend reversed sharply: ROE fell from 21.2% (2025‑06‑30) to 17.3% (2025‑09‑30) and then to 12.0% at year‑end 2025, representing the lowest reported value in the provided series. The most recent trailing‑twelve‑month ROE was 12.0% as of 2025‑12‑31.
The Gold Standard of Profitability
Return on Equity (ROE) is a powerful measure of how effectively a company's management is using the money shareholders have invested. Calculated by dividing Net Income by Shareholders' Equity, it reveals how much profit is generated for every dollar of equity capital.
A consistently high ROE (typically above 15-20%) is often the signature of a "quality" business with a durable competitive advantage. It indicates that the company can generate high returns on its own capital, which it can then reinvest at these high rates to compound value over time.
What to Look For:
How the company generates and deploys its cash
UNITEDHEALTH GROUP INC’s trailing twelve‑month operating cash flow has moderated in recent quarters after a mid‑2025 peak. Operating cash rose to $28.96B at 2025-06-30, then fell to $20.96B at 2025-09-30 and to $19.70B at 2025-12-31, following earlier variability through 2024 and 2023.
Investing cash outflows have narrowed from larger negatives in 2023–2024 toward more moderate outflows in 2025: investing cash was -$14.26B at 2025-03-31, -$8.29B at 2025-06-30, -$7.19B at 2025-09-30 and -$8.69B at 2025-12-31. Financing activity has been a net use of cash across recent TTM periods, with outflows widening to -$18.39B (2025-06-30) and -$18.95B (2025-09-30) before moderating to -$11.64B at 2025-12-31. The most recent operating cash flow (TTM) was $19.70B, investing cash flow (TTM) was -$8.69B, and financing cash flow (TTM) was -$11.64B.
Understanding Company Strategy
Capital allocation refers to how management decides to spend and invest the company's cash. Analyzing the three primary categories of cash flow reveals a company's true operational strategy:
What to look for: Is the company bootstrapping (funding growth solely from operating cash)? Are they borrowing to fund aggressive expansion or dividends? Or are they capital raising by issuing new shares, potentially diluting your ownership? A healthy, mature company typically generates strong operating cash, moderately invests in growth, and returns the surplus to shareholders through financing activities.
Trailing Twelve Months
Net assets attributable to each share — the accounting floor of intrinsic value
Why Book Value per Share Matters
Book value per share is the net worth of the company — total assets minus total liabilities — divided by shares outstanding (split-adjusted). It represents the theoretical liquidation value per share if every asset were sold and every liability repaid at balance-sheet carrying values. It is the accounting foundation upon which much of equity valuation is built.
A steadily rising book value per share is one of the most reliable signals of compounding wealth creation. It means the company is retaining earnings and building net worth faster than it is returning capital or eroding it. Warren Buffett famously tracked Berkshire Hathaway's book value per share for decades as his primary measure of intrinsic value growth.
Context is essential. Asset-heavy businesses (banks, manufacturers, utilities) should be judged by book value more directly than asset-light businesses (software, consumer brands), where intangible assets like intellectual property and customer loyalty may far exceed their balance-sheet carrying values. A company trading at a large premium to book value is not necessarily overvalued — it may simply possess competitive advantages that accounting rules do not capture. Conversely, a declining book value per share — especially over multiple years — is a serious warning sign of capital destruction.
How much of the company is financed by debt versus shareholders' equity
Reading the Debt-to-Equity Ratio
The debt-to-equity (D/E) ratio compares total financial debt to shareholders' equity. A ratio of 1.0 means the company has borrowed one dollar for every dollar of equity; a ratio of 2.0 means it has borrowed twice as much as it owns. Financial leverage amplifies both returns and risk: in good times, debt turbocharges equity returns; in bad times, it accelerates losses and can threaten solvency.
Trends matter more than a single number. A rising D/E ratio can mean the company is taking on debt to fund growth — potentially value-creating if returns exceed the cost of capital. But it can also mean equity is being eroded through losses or that the business is borrowing simply to sustain operations. A falling D/E ratio generally reflects strengthening financial health: earnings are being retained, debt maturities are being paid down, or both.
Industry norms vary enormously. Capital-intensive sectors (utilities, real estate, financials) routinely carry high D/E ratios that would be alarming in, say, a technology company. Always compare against sector peers. As a rough rule of thumb, a D/E above 2× in a cyclical business warrants careful scrutiny of interest coverage and refinancing risk.
Short-term liquidity — can the company cover its near-term obligations?
Liquidity: Can the Business Pay Its Bills?
The current ratio is calculated as current assets divided by current liabilities. A ratio of 1.5 means the company has $1.50 of short-term assets — cash, receivables, inventory — for every $1.00 of obligations due within the next twelve months. It is the most direct measure of near-term financial resilience: can the business meet its obligations without needing to raise new capital or sell long-term assets at a discount?
A ratio above 1.0 is generally healthy, meaning current assets exceed current liabilities. A ratio consistently above 2.0 may indicate the company is holding excess cash or inventory that could be deployed more productively. A ratio below 1.0 is a warning sign — the company is relying on future cash generation or external financing to cover its near-term obligations, which is manageable in normal conditions but dangerous during a downturn.
Trends and context matter.A declining current ratio isn't always alarming — highly efficient businesses (e.g., large retailers with reliable daily cash flows) often run leaner balance sheets intentionally. Conversely, a rapidly rising current ratio can signal slowing sales causing inventory to build, or customers taking longer to pay. Always compare the trend against industry peers and cross-reference with the cash flow statement to assess whether the business is genuinely liquid or just holding non-cash current assets.
How much the market is paying for each dollar of company earnings
Over the most recent five quarters UNITEDHEALTH GROUP INC’s trailing twelve-month P/E fell from 32.0x on 2024-12-31 to 21.6x on 2025-03-31 and then to a trough of 13.3x on 2025-06-30, before recovering to 17.9x on 2025-09-30 and 24.9x on 2025-12-31. This sequence shows a pronounced contraction through mid-2025 followed by a material re-expansion in the second half of 2025.
Looking further back, the P/E moved from single digits and low teens in the early 2010s into a mostly 20–30x range in recent years, with a peak of 37.2x on 2024-09-30. The most recent Price-to-Earnings (P/E) ratio was 24.9x.
What Is the PE Ratio?
The Price-to-Earnings (PE) ratio is one of the most widely used valuation metrics in investing. It divides the current stock price by the company's earnings per share (EPS), revealing how much investors are willing to pay for each dollar of earnings. A high PE can signal that the market expects strong future growth, while a low PE may suggest undervaluation—or reflect genuine concerns about the company's prospects.
Context matters:PE ratios vary significantly across industries. High-growth technology companies routinely trade at PE ratios above 30x or 40x, while mature, low-growth sectors like utilities or financials often trade closer to 10–15x. Always compare a company's PE to its own history and its industry peers, not just an absolute number.
What to Look For:
Key Insight:The PE ratio is a snapshot of market sentiment and expectations. Tracking it over time alongside earnings trends reveals whether the market's valuation has expanded or contracted—and whether that change is justified by fundamentals.